Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Aspergillosis

Clinical Trial Details

Overview

Research Study Summary

Patients are needed to participate in a clinical research study to evaluate Invasive Aspergillosis, Acute Leukemia, Biomarkers or Stem Cell Transplantation

Research Study Title

Open, Prospective, Multicenter Trial to Evaluate the Clinical Significance of Combined Serological (Galactomannan ELISA, 1->3-β-D Glucan Assay) and Molecular (Nested Aspergillus PCR Assay, Multifungal DNA Microarray) Diagnostic Assays to Detect and Characterize Fungal Pathogens in Bronchoalveolar Lavage (BAL) and Blood Samples of Hematological High Risk Patients and to Detect Point Mutations Conferring Azole Resistance

Purpose

The aim of our prospective and multicentre diagnostic study is therefore to elucidate on the sensitivity and specificity rates of these serologic markers in combination with molecular tools (both an Aspergillus specific and a multifungal PCR based assay), as serologic mark-ers are not pathogen-specific, and furthermore to define species-specific cut-off values for BDG in BAL samples.

Additionally, if genomic material of Aspergillus fumigatus is detected by PCR in a clinical sample, we investigate fungal DNA for point mutations in the cyp51A gene mediating resis-tance against common mould-active triazoles with novel rapid, sensitive and specific, non-culture-based PCR-assays and sequencing to optimize antifungal treatment as early as pos-sible.

To Learn more
Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Lead Sponsor

Heidelberg University

Duration

25 Months

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years and up

Inclusion Criteria:

  • acute leukemia or after allogeneic stem cell transplantation

  • febrile neutropenia

  • lung infiltrates suggestive for fungal infection (halo sign. nodules, air-crescent sign)

Exclusion Criteria:

  • missing informed consent

  • other underlying diagnosis

Site Locations (1)

Country State City Zip Facility and Contact
Germany Mannheim 68167 University Hospital Mannheim
Dieter Buchheidt, MD
+49.621.383.4115
dieter.buchheidt@umm.de

Dieter Buchheidt, MD
Principal Investigator

Mark Reinwald, MD
Sub-Investigator

Contact

Dieter Buchheidt, MD
+49.621.383.4115
E-mail:

NCT ID: NCT01695512

Date Last Changed: March 27, 2014

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.